{"title":"Improvement of Hailey-Hailey Disease Following Administration of Dupilumab.","authors":"Shravya Kichena, Jocelyn Carnicle, Mara Haseltine","doi":"10.36849/JDD.8060","DOIUrl":null,"url":null,"abstract":"<p><p>Hailey-Hailey disease (HHD) is a rare, chronic skin disorder characterized by recurrent inflammatory plaques with painful blisters, erosions, and macerations. We report a case of a 40-year-old female with clinical and pathological findings consistent with HHD. After numerous unsuccessful treatments, including the use of antiseptic washes, topical and oral medications, and injections, the patient was started on dupilumab (300 mg/2 mL syringes every 2 weeks). After 4 months of treatment, there was a clearance of plaques and resolution of pain with only minimal residual erythema. This response was maintained with no reported side effects. Dupilumab may be an effective and safe treatment option for refractory HHD, but it necessitates further research. J Drugs Dermatol. 2025;24(4):410-412. doi:10.36849/JDD.8060.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"410-412"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8060","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Hailey-Hailey disease (HHD) is a rare, chronic skin disorder characterized by recurrent inflammatory plaques with painful blisters, erosions, and macerations. We report a case of a 40-year-old female with clinical and pathological findings consistent with HHD. After numerous unsuccessful treatments, including the use of antiseptic washes, topical and oral medications, and injections, the patient was started on dupilumab (300 mg/2 mL syringes every 2 weeks). After 4 months of treatment, there was a clearance of plaques and resolution of pain with only minimal residual erythema. This response was maintained with no reported side effects. Dupilumab may be an effective and safe treatment option for refractory HHD, but it necessitates further research. J Drugs Dermatol. 2025;24(4):410-412. doi:10.36849/JDD.8060.
期刊介绍：
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
